Corline Biomedical AB reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 10.95 million. Revenue was SEK 10.96 million. Net income was SEK 1.97 million. Basic earnings per share from continuing operations was SEK 0.09. Diluted earnings per share from continuing operations was SEK 0.09.
For the nine months, sales was SEK 22.57 million. Revenue was SEK 22.79 million. Net income was SEK 1.99 million. Basic earnings per share from continuing operations was SEK 0.09. Diluted earnings per share from continuing operations was SEK 0.09.